LOGIN  |  REGISTER
C4 Therapeutics
Amneal Pharmaceuticals

Netramark Retains Renmark Financial Communications

May 05, 2023 | Last Trade: C$0.92 0.00 0.00

Toronto, ON - TheNewswire - May 5, 2023 - NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE:AIAI) (Frankfurt:8TV) (OTC:AINMF) announces that it has retained the services of Renmark Financial Communications Inc. (“Renmark”) to manage its investor relations activities with financial advisors, portfolio managers, family offices and institutional investors.

“We are pleased to announce that we have selected Renmark to reinforce NetraMark’s profile in the financial community and enhance the visibility of our company.  We chose Renmark because its standards and methodologies fit best with the message that we wish to communicate to the investing public,” said CEO, George Achilleos.

In consideration of the services to be provided, NetraMark will pay Renmark a monthly cash fee equal to CAD $9,000, starting May 1, 2023, for a period of 7 months ending on November 30, 2023, and monthly thereafter.

Renmark does not have any interest, directly or indirectly, in NetraMark Holdings or its securities, or any right or intent to acquire such an interest.

About NetraMark

NetraMark is a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the Pharmaceutical industry.  Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously.  This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI / ML methods.  The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and / or efficacy of treatment.

For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR).

Company contact information: Swapan Kakumanu - CFO | This email address is being protected from spambots. You need JavaScript enabled to view it. | 403-681-2549

About Renmark

Renmark Financial Communications Inc.

James McFarland: This email address is being protected from spambots. You need JavaScript enabled to view it.

1800 - 130 King Street West, Toronto, ON M5X1E3

Tel: (416) 644-2020 or (212) 812-7680

www.renmarkfinancial.com

Forward-Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation including statements regarding the terms of Renmark’s engagement which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events.  Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy.  Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact.  The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements.  Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.  New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com including our Management’s Discussion and Analysis for the year ended September 30, 2022.  These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB